美通社

2024-10-09 13:38

The CDE has Granted Breakthrough Therapy Designation to LBL-024, a Bispecific Antibody that Targets PD-L1 and 4-1BB, Developed by Leads Biolabs, for the Treatment of Extrapulmonary Neuroendocrine Carcinoma.

NANJING, China, Oct. 9, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") announced that Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation to LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by Leads Biolabs with global intellectual property rights, for the treatment of the patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC) who have progressed after receiving two or more lines of chemotherapy. The Breakthrough Therapy Designation awarded to LBL-024 stems from its remarkable clinical efficacy and safety profile in patients with advanced EP-NEC who failed in second-line and above chemotherapy. The current clinical data demonstrate that LBL-024 monotherapy has more than doubled both the Objective Response Rate (ORR) and Overall Survival (OS) compared to existing treatments for this disease.

Breakthrough Therapy refers to innovative or improved drugs that treat life-threatening conditions or significantly impact quality of life, where no effective treatment exist, or there is sufficient evidence that the therapy offers clear advantages over existing treatment options. In July 2012, the U.S. Food and Drug Administration (FDA) pioneered the "Breakthrough Therapy" review process, complementing fast track, accelerated approval, and priority review mechanisms. By accelerating the approval process and fostering closer collaboration, Breakthrough Therapy Designation facilitates faster development and market access for drugs with significant clinical potential. Historically, FDA data suggests that Breakthrough Therapy Designation can reduce time-to-market by approximately 2.5 years on average.

In July 2020, CDE officially introduced the Breakthrough Therapy Designation concept in China.  Products granted Breakthrough Therapy Designation status will receive closer guidance and various forms of support to ensure that patients are provided with new treatment options as soon as possible. 

Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, said "According to historical data from the China Drug Review Annual Report, only a few products are eligible for Breakthrough Therapy Designation, and even fewer have been approved. The designation for LBL-024 is another proof of the robust R&D capabilities of Leads Biolabs, and it is also a major victory for Leads Biolabs' insistence on focusing on the first-in-class product R&D strategy for the global market. Leads Biolabs will vigorously pursue the global clinical development of LBL-024, with the anticipation of offering more effective treatment options for patients with EP-NEC at the earliest opportunity."

Dr. Xiaoqiang Kang, founder, chairman and CEO of Leads Biolabs, said "The Breakthrough Therapy granted by the CDE prioritizes candidates that demonstrate exceptional clinical data, differentiated targets, and therapies with a high degree of efficacy certainty. This Designation represents the highest threshold and most prestigious qualification within China's pharmaceutical regulatory system, functioning as a crucial benchmark for uncovering valuable new drug projects. Leads Biolabs has consistently embraced differentiated innovation, and we eagerly anticipate the timely market introduction of LBL-024 as a novel immunotherapy, following the groundbreaking successes of anti-PD-1/PD-L1, CTLA-4, and LAG-3."

About LBL-024

LBL-024 is a tetravalent bispecific antibody that simultaneously targets PD-L1 and 4-1BB, serving dual functions: blocking the immunosuppressive PD-1/PD-L1 pathway, and selectively co-stimulating 4-1BB in the tumor microenvironment to enhance immune responses. The dual functions of LBL-024—lifting PD-1/PD-L1 immune inhibition and intensifying 4-1BB modulated T cell activation—synergistically enhance the anti-tumor immune response.

About EP-NEC

Neuroendocrine carcinoma (NEC) is a class of poorly differentiated, high-grade neuroendocrine neoplasms (NENs), which originate in the diffuse neuroendocrine cell system and can occur in many different sites. NEC can be categorized into pulmonary NEC and EP-NEC. EP-NEC exhibits similar highly aggressive and metastatic characteristics to small cell lung cancer (SCLC). Most patients are diagnosed at a later stage or already have distant metastases, resulting in rapid disease progression and a poor prognosis.

Currently, the primary first-line treatment for advanced EP-NEC involves platinum-based chemotherapy, achieving an overall response rate (ORR) of approximately 30% to 50%, with a median overall survival (mOS) of only approximately one year. Treatment options for advanced EP-NEC are limited, and there are no standard treatment strategies for patients who progress beyond second-line chemotherapy. These underscore the urgency to develop novel therapeutic approaches.

About Leads Biolabs

Nanjing Leads Biolabs Co., Ltd is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address underserved medical needs in oncology, autoimmune, and other severe diseases both in China and globally. Backboned by our proprietary technology platforms and robust drug development capabilities, we have curated a rationally designed and differentiated pipeline of 12 innovative drug candidates, six have successfully progressed into the clinical stage. Leads Biolabs is committed to providing safe, effective, accessible and affordable new drugs to address the unmet needs of patients around the world.

source: Leads Biolabs

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞! ► 即睇詳情

人氣文章
最近7天
1
高息定存 | 富邦推快閃定存優惠3個月3.9厘,華僑188日3.68厘
2
高息定存 | 6個月港元定存3.8厘新高,188日快閃優惠3.68厘
3
專訪|林本利系列專訪逢周五登場,股市篇:勿驚美股調整,港股那些可以放心買那些勿沾手(有片)
4
專訪|林本利系列專訪一連三個周五登場,樓市篇:中原指數長線重返180,買樓勿買新樓(有片)
5
高息定存 | 工銀亞洲推3個月5厘息搶新客,招商永隆推快閃優惠
6
神州經脈 | 特別國債或發3萬億,滬指逼近三千四,日外相訪華
7
高息定存 | 信銀國際上調1個月定存年息至高達3.88厘
8
回顧展望-新股復燃 | 政策市激發IPO 惟六成新股破發損行情
9
高息定存 | 聖誕前夕銀行加存息吸資金,大眾3個月加至3.6厘
10
回顧展望-國際形勢 | 全球動盪戰火連天,特朗普時代重臨
11
回顧展望-共渡時艱 | 表列機構對今明年本港經濟增長預測
12
回顧展望-樓盡六壬 | 甲廈租金明年料跌9%,華潤頻買民生商場
13
【FOCUS】「晶片戰」揮新大棒,技術制華恐適得其反
14
【FOCUS】「無厘頭」減息釀驚嚇,長債失控顯聯儲失信譽
15
【FOCUS】零售寒冬襲京滬港,逆市奇葩值借鏡
16
神州經脈 | 工業利潤降幅收窄,低空經濟發展司成立,滬指全周升
17
今日焦點股 | 據報螞蟻集團重組架構,劉政或出任首席財務官
18
港股 | 蕭猷華:恒指料退守至18600點,宜逢低吸納
19
內銀股 | 人行再提擇機減息降準,內銀獲中金唱好,應該點部署?
20
神州經脈 | PMI遜預期,滬指全年止跌回升,人幣年度貶幅擴
21
神州經脈 | 換手機可獲政府補貼,政策利率將降,滬指周挫逾5%
22
回顧展望-國際金融 | 金融市場現重要轉折,戰亂刺激避險
23
新股掛牌 | 布魯可首日掛牌升41%,每手賺7395元
24
回顧展望-息息相關 | 銀行股明年看好滙控,重組有利減低支出
25
高息定存 | 一周高息合集,銀行年尾搶資金,大眾3個月3.6厘
26
神州經脈 | 青年失業率三連降,人行約談債市激進機構,人幣續跌
27
大國博弈 | 【FOCUS】騰訊商湯寧德重挫,CMC清單劍指軍民融合
28
高息定存 | 一周高息合集,恒生1個月定存4厘,工銀亞洲3個月最高5厘
29
【FOCUS】華府停擺鬧劇又起,馬斯克功力再進化
30
港股 | 蕭猷華:恒指維持19700點至21000點上落
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【etnet 賞你】賞 MOKO x Cheeky Cheeky「厚」有福氣利是封 及「熊 MEOW 」火柴盒造型年曆卡!

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

秋天養生食療

山今養生智慧

輕鬆護老